NINJ1 plays a vital role in the release of neutrophil extracellular traps during acute lung injury.

Summary

Using patient neutrophils and mouse ALI models, the study identifies NINJ1 oligomerization as essential for NET release and lung injury. Genetic disruption of Ninj1 abolishes NETs, improves pulmonary function, and reduces mortality, with K45 and N60 residues critical for oligomerization. NINJ1 emerges as a druggable target for ALI/ARDS.

Key Findings

• NINJ1 is highly expressed in pro-inflammatory neutrophil subpopulations in ALI by single-cell RNA-seq and hotspot analysis.
• NINJ1 oligomerization is essential for NET release in neutrophils from ARDS patients and ALI mice; K45 and N60 are critical residues.
• Neutrophil-specific Ninj1 ablation abolishes NET release, mitigates pulmonary dysfunction, and reduces ALI-related lethality.

Clinical Implications

Pharmacologic inhibition of NINJ1 oligomerization could reduce NET-driven lung injury in ARDS. Biomarker development around NINJ1 expression may stratify patients for NET-targeted therapies.

Limitations

• Preclinical study without interventional pharmacology testing of NINJ1 inhibitors
• Quantitative clinical correlation and patient cohort size details are limited in the abstract

Future Directions

Develop and test selective NINJ1 oligomerization inhibitors; validate NINJ1 as a biomarker and therapeutic target in prospective ARDS cohorts and large-animal models.